Cerchietti Leandro, Leonard John P
1Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY.
Hematology Am Soc Hematol Educ Program. 2013;2013:591-5. doi: 10.1182/asheducation-2013.1.591.
Diffuse large B-cell lymphoma, the most common lymphoma subtype, is curable in the majority of patients. However, one of the greatest unmet needs in lymphoma treatment remains novel approaches to prevent relapsed or refractory disease. Genomic profiling has provided important prognostic information that is being used in the development of novel therapeutic strategies currently in clinical trials. It is clear, however, that epigenetic alterations provide an additional series of targets that can be pharmacologically modified and offer great potential to improving patient outcomes. Greater understanding of this area is providing important new insights that are now being explored in the clinical setting. Demethylating agents and drugs that disrupt histone modifiers are in early clinical trials with promising results, and other approaches targeting epigenetic pathways are in active preclinical and early clinical development.
弥漫性大B细胞淋巴瘤是最常见的淋巴瘤亚型，大多数患者可治愈。然而，淋巴瘤治疗中最大的未满足需求之一仍然是预防复发或难治性疾病的新方法。基因组分析提供了重要的预后信息，目前正在用于临床试验中新型治疗策略的开发。然而，很明显，表观遗传改变提供了一系列额外的靶点，可以通过药理学方法进行修饰，并且在改善患者预后方面具有巨大潜力。对这一领域的更深入了解正在提供重要的新见解，目前正在临床环境中进行探索。去甲基化剂和破坏组蛋白修饰剂的药物正处于早期临床试验阶段，结果令人鼓舞，其他针对表观遗传途径的方法也正处于积极的临床前和早期临床开发阶段。
